Trial reportDrug design, development and therapy2025
The Median Effective Concentration (EC50) of Alfentanil Combined with Propofol Closed-Loop Targeted Infusion in Super-Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP).
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the median effective concentration (EC50) of alfentanil combined with propofol closed-loop targeted infusion when used for sedation in super-elderly endoscopic retrograde cholangiopancreatography (ERCP) patients. Patients and Methods: A total of 28 super-elderly patients (>85 years old) undergoing elective ERCP from April to September 2024 were enrolled to receive target-controlled continuous infusion of alfentanil with an initial infusion concentration of 50ng/mL, and the continuous infusion concentration was determined according to the Dixon up and down method, and the incremental/decremental gradient of alfentanil was set at 10ng/mL. The observation was terminated after 8 reflexes. The EC50 of target-controlled infusion of alfentanil combined with propofol in the operation of ERCP in super-aged patients was calculated. HR and MAP were recorded at the time of entering the room at rest (T0), after anesthesia induction (T1), before duodenoscope placement (T2), and within 3 minutes after duodenoscope placement (T3). Results: In this study, the EC50 of alfentanil combined with propofol target-controlled infusion during ERCP in super-elderly patients was determined to be 36.52ng/mL (95% confidence interval [CI]: 32.12-41.71ng/mL). Among the 28 patients, 27 patients (96.43%) had a change in HR less than 20% of baseline during duodenoscopy, and 1 patient (3.57%) had a change in HR more than 20% of baseline during duodenoscopy. Of the 28 patients, 26 (92.86%) had a MAP change of less than 20% of baseline during duodenoscopy, and 2 (7.14%) had a MAP change of more than 20% of baseline. Conclusion: The EC50 of alfentanil combined with propofol by closed-loop target-controlled infusion during ERCP in super-elderly patients is 36.52ng/mL. At this concentration level, the patients can be satisfied with surgical anesthesia and maintain relatively stable hemodynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.